Table 3.
Comparison of SLE and RA Subjects with FRS-low/ACC-high Discordant versus Concordant 10-year Framingham Cardiovascular Risk Scores and 2013 ACC/AHA Cardiovascular Risk Scores
| FRS-low/ACC-high Discordant (N=22) | Concordant (N=231) | p value | ||
|---|---|---|---|---|
| Demographic Characteristics | ||||
| Age (years) | Mean ± SD | 65.4 ± 7.2 | 52.2 ± 9.3 | <0.01 |
| Female | N (%) | 20 (90.9%) | 206 (89.2%) | 0.80 |
| African-American race | N (%) | 5 (22.7%) | 17 (7.4%) | 0.02 |
| Cardiovascular Clinical Characteristics | ||||
| Body mass index (kg/m2) | Mean ± SD | 28.9 ± 6.0 | 26.8 ± 6.3 | 0.15 |
| Systolic blood pressure (mm Hg) | Mean ± SD | 140 ± 18 | 121 ± 18 | <0.01 |
| Diastolic blood pressure (mm Hg) | Mean ± SD | 73 ± 13 | 70 ± 13 | 0.41 |
| Total cholesterol (mg/dL) | Mean ± SD | 179 ± 29 | 185 ± 39 | 0.51 |
| LDL cholesterol (mg/dL) | Mean ± SD | 93 ± 23 | 96 ± 33 | 0.66 |
| HDL cholesterol (mg/dL) | Mean ± SD | 61 ± 17 | 64 ± 19 | 0.50 |
| Triglycerides (mg/dL) | Mean ± SD | 126 ± 41 | 121 ± 67 | 0.69 |
| Current smoker | N (%) | 1 (4.6%) | 14 (6.1%) | 0.77 |
| Diabetes | N (%) | 8 (36.4%) | 6 (2.6%) | <0.01 |
| Current use of anti-hypertensive medication | N (%) | 15 (68.2%) | 85 (36.8%) | <0.01 |
| Rheumatologic Clinical Characteristics | ||||
| hsCRP (mg/L) | Mean ± SD | 7.3 ± 10.4 | 3.6 ± 5.9 | 0.01 |
| Current use of prednisone therapy | N (%) | 6 (27.3%) | 91 (40.4%)* | 0.23 |
| Current daily prednisone dose among prednisone users (mg) | Mean ± SD | 7.3 ± 2.3 | 7.5 ± 4.6 | 0.91 |
| Disease duration (years) | Mean ± SD | 23.5 ± 13.1 | 17.4 ± 10.2 | 0.01 |
Values are the mean ± standard deviation (SD) for continuous variables and N (%) for categorical variables.
p values were calculated using chi-squared tests for categorical variables and using independent t-tests for continuous variables.
Laboratory studies were collected in non-fasting conditions.
A subject with a FRS-low/ACC-high discordant cardiovascular risk score is defined as a subject who has a 10-year Framingham cardiovascular risk score less than 10% and a 10-year 2013 ACC/AHA cardiovascular risk score greater than or equal to 7.5%.
6 subjects with concordant cardiovascular risk scores were missing data on current use of prednisone therapy; percentage noted excluded those with missing data.